Geode Capital Management
TCRT icon

Geode Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Geode Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.5K Buy
22,560
+2,824
+14% +$8.45K ﹤0.01% 4253
2025
Q4 		$63.8K Buy
19,736
+3,945
+25% +$12.8K ﹤0.01% 4194
2025
Q3 		$38.5K Sell
15,791
-155
-1% -$442 ﹤0.01% 4345
2025
Q2 		$77.4K Buy
15,946
+336
+2% +$1.01K ﹤0.01% 4128
2025
Q1 		$22.6K Buy
15,610
+394
+3% +$646 ﹤0.01% 4327
2024
Q4 		$28.9K Sell
15,216
-1,117
-7% -$2.48K ﹤0.01% 4333
2024
Q3 		$53.7K Sell
16,333
-26
-0.2% -$93 ﹤0.01% 4250
2024
Q2 		$114K Buy
16,359
+1,317
+9% +$15.7K ﹤0.01% 4097
2024
Q1 		$272K Hold
15,042
– – ﹤0.01% 3833
2023
Q4 		$160K Buy
15,042
+619
+4% +$7.46K ﹤0.01% 4015
2023
Q3 		$285K Sell
14,423
-607
-4% -$26.2K ﹤0.01% 3828
2023
Q2 		$1.15M Buy
15,030
+786
+6% +$63.6K ﹤0.01% 3291
2023
Q1 		$1.35M Buy
14,244
+282
+2% +$26.9K ﹤0.01% 3218
2022
Q4 		$1.36M Buy
13,962
+119
+0.9% +$17.2K ﹤0.01% 3216
2022
Q3 		$3.57M Buy
13,843
+11
+0.1% +$3.19K ﹤0.01% 2855
2022
Q2 		$2.57M Sell
13,832
-9,678
-41% -$925K ﹤0.01% 3026
2022
Q1 		$2.3M Sell
23,510
-360
-2% -$46.2K ﹤0.01% 3192
2021
Q4 		$3.9M Buy
23,870
+1,606
+7% +$353K ﹤0.01% 3028
2021
Q3 		$6.08M Sell
22,264
-1,414
-6% -$432K ﹤0.01% 2797
2021
Q2 		$9.38M Buy
23,678
+111
+0.5% +$51.8K ﹤0.01% 2502
2021
Q1 		$12.7M Buy
23,567
+2,980
+14% +$1.86M ﹤0.01% 2194
2020
Q4 		$7.78M Buy
20,587
+859
+4% +$342K ﹤0.01% 2332
2020
Q3 		$7.46M Buy
19,728
+282
+1% +$125K ﹤0.01% 2148
2020
Q2 		$9.57M Buy
19,446
+1,674
+9% +$746K ﹤0.01% 1946
2020
Q1 		$6.53M Buy
17,772
+2,926
+20% +$1.51M ﹤0.01% 1993
2019
Q4 		$10.5M Buy
14,846
+936
+7% +$644K ﹤0.01% 1978
2019
Q3 		$8.93M Buy
13,910
+542
+4% +$430K ﹤0.01% 2017
2019
Q2 		$11.7M Buy
13,368
+1,656
+14% +$1.14M ﹤0.01% 1837
2019
Q1 		$6.76M Buy
11,712
+1,365
+13% +$571K ﹤0.01% 2149
2018
Q4 		$2.9M Buy
10,347
+968
+10% +$383K ﹤0.01% 2552
2018
Q3 		$4.5M Buy
9,379
+366
+4% +$157K ﹤0.01% 2416
2018
Q2 		$4.08M Buy
9,013
+1,100
+14% +$698K ﹤0.01% 2439
2018
Q1 		$4.65M Buy
7,913
+175
+2% +$109K ﹤0.01% 2283
2017
Q4 		$4.8M Buy
7,738
+151
+2% +$108K ﹤0.01% 2236
2017
Q3 		$6.99M Buy
7,587
+173
+2% +$154K ﹤0.01% 1993
2017
Q2 		$6.92M Buy
7,414
+638
+9% +$625K ﹤0.01% 1916
2017
Q1 		$6.44M Buy
6,776
+254
+4% +$237K ﹤0.01% 1929
2016
Q4 		$5.23M Buy
6,522
+189
+3% +$170K ﹤0.01% 2035
2016
Q3 		$5.35M Buy
6,333
+345
+6% +$277K ﹤0.01% 1931
2016
Q2 		$4.93M Buy
5,988
+105
+2% +$114K ﹤0.01% 1923
2016
Q1 		$6.55K Sell
5,883
-191
-3% -$195K ﹤0.01% 1683
2015
Q4 		$7.57M Buy
6,074
+569
+10% +$941K ﹤0.01% 1572
2015
Q3 		$7.44M Buy
5,505
+193
+4% +$319K ﹤0.01% 1559
2015
Q2 		$9.56M Buy
5,312
+841
+19% +$1.31M 0.01% 1445
2015
Q1 		$7.22M Buy
4,471
+623
+16% +$923K ﹤0.01% 1618
2014
Q4 		$2.93M Buy
3,848
+252
+7% +$134K ﹤0.01% 2172
2014
Q3 		$1.42M Buy
3,596
+29
+0.8% +$14K ﹤0.01% 2577
2014
Q2 		$2.16M Buy
3,567
+15
+0.4% +$8.35K ﹤0.01% 2330
2014
Q1 		$2.44M Buy
3,552
+487
+16% +$326K ﹤0.01% 2218
2013
Q4 		$2M Buy
3,065
+699
+30% +$416K ﹤0.01% 2293
2013
Q3 		$1.4M Buy
2,366
+155
+7% +$69.9K ﹤0.01% 2390
2013
Q2 		$697K Buy
+2,211
New +$614K ﹤0.01% 2680

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Geode Capital Management's TCRT Position: Q1 2026 in Review

Geode Capital Management increased its Alaunos Therapeutics (TCRT) stake by 14% in Q1 2026, buying an estimated $8.45K and bringing the position to 22,560 shares worth $64.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4253.

Geode Capital Management first reported a position in TCRT in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.7M in Q1 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Geode Capital Management held 22,560 shares of Alaunos Therapeutics worth $64.5K as of Q1 2026.
  • Geode Capital Management bought 2,824 Alaunos Therapeutics shares in Q1 2026, an estimated $8.45K.
  • Alaunos Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4253 holding.
  • Geode Capital Management first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Geode Capital Management's Alaunos Therapeutics position peaked at $12.7M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.